US FDA extends review of Pfizer's Fablyn until January
This article was originally published in Scrip
Executive Summary
The US FDAhas extended the review period for Pfizer's selective oestrogen receptor modulator (SERM), Fablyn (lasofoxifene), by three months until January to analyse complete five-year data from the pivotal PEARL study, the company said. In September an advisory panel endorsed approval of Fablyn for the treatment of osteoporosis in women. Committee members generally recommended the SERM for second-line use owing to safety issues raised during clinical trials, including increases in all-cause mortality, thromboembolic events and gynaecological problems. At the time of the meeting preliminary five-year data from the 8,556-patient, placebo-controlled PEARL study were available, but a final report had not been submitted to the agency. The FDA concluded that three-year PEARL data demonstrated lasofoxifene was effective in significantly reducing the risk of new or worsening radiographic vertebral fractures.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.